BACKGROUND: Despite the progress made in recent years, @entity1582 is still considered an incurable disease. Most survival data come from clinical trials. Little is known about the outcome in unselected real-life @entity1 . METHODS: Overall survival was analyzed in a cohort of newly diagnosed symptomatic @entity1582 @entity1 , over the last three decades, in a single institution population-based study. RESULTS: 582 consecutive @entity1582 @entity1 were included in the study. Survival increased over time in @entity1 younger than 65 years but did not reach statistical significance in @entity1 with 65 years or older. The prognostic factors associated with overall survival were the International Staging System, the serum @entity880 dehydrogenase level, the @entity8 , the realization of autologous stem cell transplantation, and the presence of concomitant @entity2783 . Overall survival shows a steady improvement over time. INTERPRETATION: The survival of @entity1582 is improving progressively in real-life @entity1 , particularly after the widespread use of the novel agents. A comprehensive assessment of comorbidity can help to explain the huge heterogeneity of @entity1582 outcome. The optimization of current therapeutic resources as well as the incorporation of new drugs will allow further improvement of survival in the coming years.

Trends in survival of XXXX : A thirty-year population-based study in a single institution.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal impairment'] @entity2783 :: ('MESH:D000686', 'Disease') :: ['amyloidosis'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'myeloma'] @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate']
@entity1582 :: (MESH:D009101,Disease) :: ['multiple myeloma']
